人参多糖注射液联合DC干预肺、肠癌Th1/Th2研究

Research on Ginseng Polysacchride Injection Add DC Treatment in Th1/Th2 of NSCLC and CRC Patients Under Theory of Treating Different Diseases with Same Method

摘要:

目的：探索人参多糖注射液（GPS）联合树突状细胞（DC） 对非小细胞肺癌（NSCLC）、大肠癌（CRC）异病同治的Th1/Th2相关肿瘤免疫调节机制。方法：80例NSCLC，CRC患者（各40例）按照不同疾病及治疗方法随机分4组：NSCLC对照组（DC治疗）、NSCLC研究组（GPS联合DC治疗）、CRC对照组（DC治疗）、CRC研究组（GPS联合DC治疗），每组各20例。4组肿瘤患者干预前后分别检测血清γ干扰素（INF-γ）、白细胞介素4（IL-4）、白细胞介素2（IL-2）、白细胞介素5（IL-5）。结果：4组肿瘤患者治疗前后比较，Th1（INF-γ，IL-2）及Th1/Th2（INF-γ/IL-4，IL-2/IL-5）升高，Th2（IL-4，IL-5）降低（P<0.01）；4组肿瘤患者治疗后比较，Th1（INF-γ、IL-2）及Th1/Th2（INF-γ/IL-4，IL-2/IL-5）：NSCLC研究组>NSCLC对照组，CRC研究组>CRC对照组（P<0.05），Th2（IL-4、IL-5）：NSCLC对照组>NSCLC研究组，CRC对照组>CRC研究组（P<0.05）。结论：GPS联合DC对此两类肿瘤患者Th1/Th2皆具有不同程度调节作用，此为其异病同治作用机制之一；GPS对DC免疫调节具有协同作用。

Abstract:

Objective: To explore the mechanism of Ginseng Polysacchride injection(GPS) add dendritic cells(DC) effect on Th1/Th2 of non-small cell lung cancer(NSCLC) and colorectal cancer(CRC) patients. Method: Eight cases of NSCLC and CRC patients were divided into four groups randomly (NSCLC control group, NSCLC research group, CRC control group, CRC research group), 20 cases in each group. Using DC or GPS add DC treatment. Detect interferon-γ(INF-γ), interleukin-4(IL-4), IL-2 and IL-5 in the four groups before and after treatment. Result: Before and after treatment, Th1(INF-γ, IL-2)and Th1/Th2(INF-γ/IL-4, IL-2/IL-5) were increased and Th2(IL-4, IL-5)was decreased in four cancer groups(P<0.01). After treatment, Th1(INF-γ, IL-2) and Th1/Th2(INF-γ/IL-4, IL-2/IL-5) were showed:NSCLC research group>NSCLC control group and CRC research group>CRC control group(P<0.05);Th2(IL-4, IL-5) was showed:NSCLC control group>NSCLC research group and CRC control group>CRC research group(P<0.05). Conclusion: GPS add DC treatment has different degree of Th1/Th2 regulation in NSCLC and CRC patients, this is one of the mechanisms of treating different diseases with the same method;GPS have the assistant to DC in adjusting the immunity of cancer patients.